XERS
Income statement / Annual
Last year (2024), Xeris Biopharma Holdings, Inc.'s total revenue was $163.91 M,
an increase of 48.68% from the previous year.
In 2024, Xeris Biopharma Holdings, Inc.'s net income was -$62.26 M.
See Xeris Biopharma Holdings, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$163.91 M
|
$110.25 M
|
$110.25 M
|
$49.59 M
|
$20.16 M
|
$2.47 M
|
$1.56 M
|
$1.08 M
|
| Cost of Revenue |
$28.65 M |
$22.63 M |
$22.63 M |
$13.32 M |
$9.33 M |
$42,000.00 |
$4,000.00 |
$8,000.00 |
| Gross Profit |
$135.27 M |
$87.61 M |
$87.61 M |
$36.27 M |
$10.83 M |
$2.42 M |
$1.55 M |
$1.07 M |
| Gross Profit Ratio |
0.83 |
0.79 |
0.79 |
0.73 |
0.54 |
0.98 |
1 |
0.99 |
| Research and Development
Expenses |
$22.34 M
|
$20.97 M
|
$20.97 M
|
$25.16 M
|
$20.92 M
|
$40.65 M
|
$20.17 M
|
$10.24 M
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$21.11 M
|
$8.02 M
|
$4.06 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$146.10 M
|
$137.75 M
|
$137.75 M
|
$125.72 M
|
$73.73 M
|
$21.11 M
|
$8.02 M
|
$4.06 M
|
| Other Expenses |
$10.84 M |
-$14.14 M |
$10.84 M |
$550,000.00 |
-$280,000.00 |
$0.00 |
-$1,000.00 |
-$5,000.00 |
| Operating Expenses |
$168.44 M |
$169.55 M |
$169.55 M |
$151.43 M |
$94.37 M |
$61.77 M |
$28.18 M |
$14.30 M |
| Cost And Expenses |
$207.92 M |
$192.19 M |
$192.19 M |
$164.75 M |
$103.70 M |
$61.81 M |
$28.19 M |
$14.31 M |
| Interest Income |
$4.75 M |
$2.58 M |
$2.58 M |
$313,000.00 |
$2.97 M |
$1.61 M |
$124,000.00 |
$5,000.00 |
| Interest Expense |
$26.61 M |
$15.33 M |
$15.33 M |
$7.18 M |
$10.66 M |
$2.55 M |
$2,000.00 |
$2,000.00 |
| Depreciation &
Amortization |
$13.16 M
|
$12.67 M
|
$1.88 M
|
$1.47 M
|
$1.08 M
|
$320,000.00
|
$177,000.00
|
$116,000.00
|
| EBITDA |
-$23.74 M
|
-$69.31 M
|
-$113.67 M
|
-$80.08 M
|
-$117.80 M
|
-$57.22 M
|
-$26.38 M
|
-$13.09 M
|
| EBITDA Ratio |
-0.14 |
-0.64 |
-0.64 |
-2.31 |
-4 |
-23.42 |
-16.92 |
-12.2 |
| Operating Income Ratio
|
-0.27
|
-0.74
|
-0.74
|
-2.32
|
-4.15
|
-24.07
|
-17.11
|
-12.31
|
| Total Other
Income/Expenses Net |
-$19.49 M
|
-$14.14 M
|
-$7.57 M
|
-$7.70 M
|
-$3.66 M
|
-$736,000.00
|
$75,000.00
|
$22,000.00
|
| Income Before Tax |
-$63.50 M |
-$96.08 M |
-$96.08 M |
-$122.73 M |
-$91.25 M |
-$60.08 M |
-$26.55 M |
-$13.21 M |
| Income Before Tax Ratio
|
-0.39
|
-0.87
|
-0.87
|
-2.47
|
-4.53
|
-24.37
|
-17.07
|
-12.29
|
| Income Tax Expense |
-$1.25 M |
-$1.42 M |
-$1.42 M |
-$110,000.00 |
-$110,000.00 |
$1.81 M |
$1,000.00 |
-$3,000.00 |
| Net Income |
-$62.26 M |
-$94.66 M |
-$94.66 M |
-$122.73 M |
-$91.14 M |
-$60.08 M |
-$26.55 M |
-$13.21 M |
| Net Income Ratio |
-0.38 |
-0.86 |
-0.86 |
-2.47 |
-4.52 |
-24.37 |
-17.07 |
-12.29 |
| EPS |
-0.45 |
-0.7 |
-1.2 |
-2.88 |
-3.49 |
-4.99 |
-13.09 |
-7.17 |
| EPS Diluted |
-0.45 |
-0.7 |
-1.2 |
-2.88 |
-3.49 |
-4.99 |
-13.09 |
-7.17 |
| Weighted Average Shares
Out |
$137.67 M
|
$135.63 M
|
$79.03 M
|
$42.64 M
|
$26.11 M
|
$12.05 M
|
$2.03 M
|
$1.84 M
|
| Weighted Average Shares
Out Diluted |
$137.67 M
|
$135.63 M
|
$79.03 M
|
$42.64 M
|
$26.11 M
|
$12.05 M
|
$2.03 M
|
$1.84 M
|
| Link |
|
|
|
|
|
|
|
|
